

Dabrafenib + trametinib COMBI-d

### PRELIMINARY SCORE

**CURATIVE**



**NON-CURATIVE**




### ADJUSTMENTS

**Quality of life**



**Serious and disabling adverse effects**



**Other adjustments**



Dabrafenib + trametinib COMBI-d

### SCORE

**CURATIVE**



Overall Survival / Disease-Free Survival / Pathological Complete Response

**NON-CURATIVE**




Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

**INFORMATION**

Tumour type: Skin Cancers  
 Therapeutic Indication: Dabrafenib in combination with trametinib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation  
 Experimental Arm: Dabrafenib + trametinib  
 Control Arm: Dabrafenib

